Global /United States /Healthcare /Biotechnology /IPA

ImmunoPrecise Antibodies Ltd.

IPA

• NASDAQ: IPA • Delayed

2.13USD 2.9%

As of 13 June 2026, ImmunoPrecise Antibodies Ltd. has a market cap of $98.31M USD, ranking #25687 globally and #3950 in the United States. It ranks #2299 in the Healthcare sector, and #439 in the Biotechnology industry.

Global Rank

25687

Country Rank

3950

Sector Rank

2299

Industry Rank

439

Key Stats

Market Cap

$98.31MUSD

Enterprise Value

$97.52MUSD

Revenue (TTM)

$17.74MUSD

EBITDA (TTM)

-$6.74MUSD

Net Income (TTM)

-$21.88MUSD

EBITDA Margin

-38%

Profit Margin

-123%

PS Ratio

3.9

PB Ratio

5.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Jennifer Bath open_in_new

Employees

102

Founded

1983

IPO

03 Jan 2017

Website

ipatherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.9%	-20%	30%	273%	521%	417%	182%	-60%	-67%

News

IPA Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	IPA ImmunoPrecise Antibodies Ltd ISIN: CA45257F2008 Shares Out.: Shares Outstanding: 46.154M¹ Shares Float: 40.027M² TV: TradingView: NASDAQ: IPA SA: Stock Analysis: NASDAQ: IPA YF: Yahoo Finance: IPA GF: Google Finance: NASDAQ: IPA NQ: NASDAQ: IPA BA: Barron's: IPA MS: Morningstar: XNAS: IPA	2.13 USD	TV: TradingView: NASDAQ: IPA SA: Stock Analysis: NASDAQ: IPA YF: Yahoo Finance: IPA GF: Google Finance: NASDAQ: IPA NQ: NASDAQ: IPA BA: Barron's: IPA MS: Morningstar: XNAS: IPA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 185K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 163K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 28K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 27K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 25K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 18K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 49K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 46K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 43K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 43K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 28K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 26K%	-	Germany

chevron_leftBack